Session Information
Date: Saturday, October 6, 2018
Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment
Session Time: 1:45pm-3:15pm
Location: Hall 3FG
Objective: In recent decades, as a result of increasing the life expectancy of the population, the number of patients with Parkinsonism has increased, which leads to early disability of patients and is accompanied by significant socio-economic losses. According to foreign data (Rijk M. Et al., 1997), the incidence of parkinsonism in 100 man in the general population is 65-187 people, and in persons aged 70-79 years, 300-1800 patients. A negative feature of Parkinson’s disease in the 21st century is the obvious “rejuvenation” of the disease, which forcing to officially provide for the presence of “early parkinsonism” with the debut of the disease in 40-50 years and “juvenile” – up to 40 years.
Background: To evaluate the effectiveness of the preparation gliatilin in the injectable form of 1000 mg – 4.0 ml and in the form of 400 mg tablets in the treatment of patients with vascular Parkinsonism (VP).
Methods: The investigations were carried out in the department of neurology of the Clinic of the Tashkent Medical Academy. The subject of the study was 26 patients with vascular Parkinsonism (VP) aged 43 to 70 years (mean age 63.1 ± 7.2 years) and 16 patients with PD at the age of 47 to 72 years (mean age was 68.2 ± 5 , 7 years old) who received the preparation gliatilin as part of complex therapy. All the examined patients showed all the signs of the joint venture.
Results: The severity of cognitive functions was more pronounced in patients with PD (17,4 ± 2,8) compared with the patient with PD (20,14 ± 1,29), there was a significant decrease in the function of mental load. Analysis of cognitive functions after treatment with gliatilin for 10 days of injectable use then in a tablet form for 1 to 2 months showed an improvement in mental abilities with significant differences in patients with vascular parkinsonism.
Conclusions: The use of gliatilin is a significant component in the treatment of patients with diabetes and BP who have cognitive impairment, and also leads to improved household and work skills, and accordingly the patient does not need outside help.
To cite this abstract in AMA style:
S. Lukmonov, D. Tolibov. The use of gliatilin in the complex treatment of vascular parkinsonism [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/the-use-of-gliatilin-in-the-complex-treatment-of-vascular-parkinsonism/. Accessed May 13, 2025.« Back to 2018 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-use-of-gliatilin-in-the-complex-treatment-of-vascular-parkinsonism/